Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216723 | PMC |
| http://dx.doi.org/10.1093/jncics/pkae045 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity.
JNCI Cancer Spectr
July 2024
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, USA.
Preconception origins of asthma, allergies and lung function: The influence of previous generations on the respiratory health of our children.
J Intern Med
May 2023
Division of Early Life Origins of Chronic Lung Diseases, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.
Emerging research suggests that exposures occurring years before conception are important determinants of the health of future offspring and subsequent generations. Environmental exposures of both the father and mother, or exposure to disease processes such as obesity or infections, may influence germline cells and thereby cause a cascade of health outcomes in multiple subsequent generations. There is now increasing evidence that respiratory health is influenced by parental exposures that occur long before conception.
View Article and Find Full Text PDFGenome Editing: Learning from Its Past and Envisioning Its Future.
Eur J Health Law
April 2022
Department of Legal Studies and Political Science, Central European University Quellenstrasse 51, 1100 Vienna Austria.
With the technical possibility of genome editing, we have reached a new phase of transforming human beings and even altering our genetic legacy. Genome editing constitutes new responsibilities in many fields. Science and society have never been as dependent on each other as they are today.
View Article and Find Full Text PDFGenetic testing in patients with triple-negative or hereditary breast cancer.
Curr Opin Oncol
November 2021
Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem.
Article Synopsis
- The review discusses the rapid advancements in genetic testing for breast cancer patients, especially those with BRCA1/2 mutations, which now have broader therapeutic implications.
- It highlights a shift from traditional genetic testing methods towards more accessible, oncology-led models that integrate testing into standard cancer care, though challenges remain in interpreting results.
- The introduction of new treatments, like poly (adenosine diphosphate-ribose) polymerase inhibitors, necessitates urgent updates in genetic testing guidelines to better serve patients as predictive therapeutic biomarkers instead of just hereditary risk factors.
This issue of the Hastings Center Report (May-June 2017) features a couple of interesting takes on the governance challenges of emerging technologies. In an essay on the National Academies of Science, Engineering, and Medicine report published this February on human germ-line gene editing, Eric Juengst, a philosopher at the University of North Carolina, argues that the NASEM committee did not manage to rethink the rules. Juengst reaches what he calls an "eccentric conclusion": "The committee's 2017 consensus report has been widely interpreted as 'opening the door' to inheritable human genetic modification and holding a line against enhancement interventions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!